<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33217848</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>47</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Medical cost and healthcare utilization of amyotrophic lateral sclerosis in China: A cohort study based on hospital data from 2015 to 2018.</ArticleTitle><Pagination><StartPage>e23258</StartPage><MedlinePgn>e23258</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e23258</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000023258</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS), a specific neurodegenerative disease, imposed increased economic and utilizations burden on the healthcare system, especially with the progress of the diseases severity. However, the economic burden on Chinese ALS patients remained unclear. This study therefore was aimed to investigate medical cost and healthcare utilization for Chinese ALS patients.Longitudinal health data of over 20 million individuals, including military personnel and civilians, was collected from all Chinese military hospitals. We identified 480 patients with a first major diagnosis for ALS from 2015 to 2018, while matched 400 controlled patients on age, gender, ethnic group, geographic region, length of stay, year of diagnosis and comorbidity. Their medical cost and healthcare utilizations were then measured 1 year before, and 1 year after ALS diagnosis.The median annual medical cost of ALS patients was about 2-fold higher, 17,087 CNY during the index year than 1 year before, 7859 CNY. The highest increase in utilizations may account for medical costs on ALS patients, which was represented by hospitalizations (Odd Ratio (OR)&#x200a;=&#x200a;4.26, 95% confidence interval (CI) 3.52, 5.15), electromyography (OR&#x200a;=&#x200a;4.14, 95% CI 2.37, 7.22), nerve conduction velocity (OR&#x200a;=&#x200a;3.26, 95% CI 2.23, 4.77).This study is the first one reporting direct economic burden on Chinese ALS patients. Efforts should be made to develop cost-effective diagnostic tools in order that sources of medical cost were more effectively allocated, and this disease was detected earlier.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Health Service, PLA General Hospital, Beijing.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Occupational and Environmental Health, and the Ministry-of-Education's Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jian-Chao</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Health Service, PLA General Hospital, Beijing.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Zi-Peng</ForeName><Initials>ZP</Initials><AffiliationInfo><Affiliation>Department of Occupational and Environmental Health, and the Ministry-of-Education's Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wen-Jing</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Occupational and Environmental Health, and the Ministry-of-Education's Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jing-Yuan</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0001-7411-384</Identifier><AffiliationInfo><Affiliation>Department of Health Service, PLA General Hospital, Beijing.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Occupational and Environmental Health, and the Ministry-of-Education's Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006753" MajorTopicYN="N">Hospital Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33217848</ArticleId><ArticleId IdType="pmc">PMC7676534</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000023258</ArticleId><ArticleId IdType="pii">00005792-202011200-00063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, He J, Gao FB, et al. The epidemiology and genetics of Amyotrophic lateral sclerosis in China. Brain Res 2018;1693(Pt A):121&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486791</ArticleId><ArticleId IdType="pubmed">29501653</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 2016;7:12408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman M, Zinman L. The economic impact of amyotrophic lateral sclerosis: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2015;15:439&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">25924979</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Bian A, Jordan S, et al. Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891333</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein LM, Forshew DA. The economic impact of ALS. Neurology 1996;47: 4 Suppl 2: S126&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Liu M, Nagel G, et al. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol 2018;265:774&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29392461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang B, Chen R, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 2015;86:1075&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">26124198</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Liu J, Cao Z, et al. Analysis of disease profile, and medical burden by lead exposure from hospital information systems in China. BMC Public Health 2019;1170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712603</ArticleId><ArticleId IdType="pubmed">31455310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 2000;57:109&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellura E, Spataro R, Taiello AC, et al. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2012;114:550&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MS, Cui LY, Fan DS. Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand 2014;129:163&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23819875</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Chen L, Rosenbohm A, et al. Prognostic factors in ALS: a comparison between Germany and China. J Neurol 2019;266:1516&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">30923935</ArticleId></ArticleIdList></Reference><Reference><Citation>Robelin L, Gonzalez DAJ. Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? Biomed Res Int 2014;2014:525097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060749</ArticleId><ArticleId IdType="pubmed">24991560</ArticleId></ArticleIdList></Reference><Reference><Citation>Myrianthopoulos NC, Leyshon WC. The relation of blood groups and the secretor factor to amyotrophic lateral sclerosis. Am J Hum Genet 1967;19:607&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1706236</ArticleId><ArticleId IdType="pubmed">4963689</ArticleId></ArticleIdList></Reference><Reference><Citation>Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000;23:1488&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">11003783</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhang X, Ding X, et al. Analysis of clinical and electrophysiological characteristics of 150 patients with amyotrophic lateral sclerosis in China. Neurol Sci 2019;40:363&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30467636</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce NC, Carter GT. Electrodiagnosis in persons with amyotrophic lateral sclerosis. PM R 2013;5: 5 Suppl: S89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4590769</ArticleId><ArticleId IdType="pubmed">23523708</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkindale J, Yang W, Hogan PF, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve 2014;49:431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23836444</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly S, Heslin C, Mays I, et al. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">25285902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:426&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">25025935</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>